A Conversation With FDA Interventional Cardiology Reviewer Andrew Farb
This article was originally published in The Gray Sheet
When FDA needed experts to guide its response to the emerging drug-eluting stent thrombosis issue in 2006, it was lucky to find it already had a cardiovascular pathologist experienced with implantable devices on its review staff
You may also be interested in...
FDA plans to issue a guidance document on drug-eluting stents in the next several months to communicate new premarket and postmarket recommendations for the heavily scrutinized products
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.